Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$4.2 - $6.01 $1.05 Million - $1.5 Million
249,835 Added 312.54%
329,771 $1.39 Million
Q4 2022

Feb 14, 2023

SELL
$4.45 - $6.17 $1.35 Million - $1.87 Million
-302,750 Reduced 79.11%
79,936 $480,000
Q3 2022

Nov 14, 2022

BUY
$5.36 - $7.43 $1.05 Million - $1.45 Million
195,283 Added 104.2%
382,686 $2.23 Million
Q3 2022

Nov 14, 2022

BUY
$5.36 - $7.43 $1.05 Million - $1.45 Million
195,283 Added 104.2%
382,686 $2.23 Million
Q2 2022

Aug 16, 2022

SELL
$3.55 - $6.27 $62,764 - $110,853
-17,680 Reduced 8.62%
187,403 $1.12 Million
Q1 2022

May 17, 2022

BUY
$1.9 - $5.23 $353,654 - $973,480
186,134 Added 982.29%
205,083 $957,000
Q4 2021

Feb 15, 2022

BUY
$1.44 - $2.86 $2,347 - $4,661
1,630 Added 9.41%
18,949 $47,000
Q3 2021

Nov 16, 2021

BUY
$2.25 - $3.18 $38,967 - $55,074
17,319 New
17,319 $51,000
Q4 2020

Feb 17, 2021

SELL
$2.48 - $3.8 $38,487 - $58,972
-15,519 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$1.02 - $2.15 $15,829 - $33,365
15,519 New
15,519 $33,000
Q3 2019

Nov 14, 2019

SELL
$0.64 - $0.92 $88,531 - $127,263
-138,330 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$0.8 - $1.03 $110,664 - $142,479
138,330 New
138,330 $119,000
Q1 2019

May 16, 2019

SELL
$0.9 - $1.37 $11,333 - $17,252
-12,593 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$0.73 - $2.19 $9,192 - $27,578
12,593 New
12,593 $9,000
Q1 2018

May 15, 2018

SELL
$2.7 - $4.06 $475,661 - $715,254
-176,171 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$2.47 - $3.34 $435,142 - $588,411
176,171
176,171 $472,000

About CTI BIOPHARMA CORP


  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.